Dual “mAb” HER family blockade in head and neck cancer human cell lines combined with photon therapy

Jean-Baptiste Guy1, 2, Benoîte Méry1, 3, Edouard Ollier1, Sophie Espenel1, 2, Alexis Vallard2, Anne-Sophie Wozny1, 5, Stéphanie Simonet1, Alexandra Laurent1, Priscillia Battiston-Montagne2, Dominique Ardail1, 5, Gersende Alphonse1, Chloé Rancoule2, Claire Rodríguez-Lafrasse1, 4, 5 & Nicolas Magné1, 2

Head and neck cancer stem cells (CSCs) are highly resistant to treatment. When EGFR is overexpressed in head and neck squamous cell carcinoma (HNSCC), HER2 and HER3 are also expressed. The aim of the present study was to investigate the effect of HER1/2/3 blockade through a combination of cetuximab and pertuzumab, with or without photon irradiation, on the proliferation and migration/invasion capabilities of an HNSCC chemo- and radioresistant human cell line (SQ20B) and its corresponding stem cell subpopulation. Cell proliferation, migration and invasion were studied after treatment with cetuximab +/− pertuzumab +/− 10 Gy photon irradiation. EGFR, phospho-EGFR, HER2 and HER3 protein expression levels were studied. Activation or inhibition of the RAS/MAPK and AKT-mTOR downstream signalling cascades was investigated through phospho-AKT and phospho-MEK1/2 expression. Cetuximab strongly inhibited SQ20B and FaDu cell proliferation, migration and invasion, whereas it had little effect on SQ20B-CSCs. Cetuximab–pertuzumab combined with radiation significantly inhibited SQ20B and FaDu cell and SQ20B-CSC proliferation, migration and invasion. Cetuximab–pertuzumab with 10 Gy photon irradiation switched off both phospho-AKT and phospho-MEK1/2 expression in the three populations. The triple therapy is therefore thought to inhibit SQ20B cells, SQ20B-CSCs and FaDu cells through an AKT-mTOR and Ras-MAPK downstream signalling blockade.

Head and neck squamous cell carcinoma (HNSCC) still has a dismal prognosis, despite recent biological and technological improvements1. In the past few years, it has been shown that the epidermal growth factor receptor (EGFR) is overexpressed in more than 90% of HNSCCs2. Faced with this therapeutic target, cetuximab, a mouse–human chimeric monoclonal antibody directed against EGFR, was developed and shown to significantly improve locoregional control, progression-free survival and overall survival when used concomitantly with radiotherapy (RT)3, 4. These improvements were nevertheless counterbalanced by high rates of local and distant recurrences5, 6 leading to specific mortality in the short or medium term5. The epithelial-to-mesenchymal process, giving invasion/migration capacities to cancer cells, is thought to be the root of all these recurrences. Furthermore, the presence of a subpopulation of cancer cells showing particularly high migratory potential7, known as cancer stem cells (CSCs), has been revealed in HNSCC8. Moncharmont et al.9 showed that a HNSCC CSC subpopulation with low EGFR expression could resist cetuximab, giving the first biological explanation for clinical reports. Moreover, increasing evidence suggests that cancers that initially respond to EGFR may subsequently become refractory, 1Université Lyon 1, UMR CNRS 5822 /IN2P3, IPNL, PRISME, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Faculté de Médecine Lyon-Sud, F-69921, Oullins cedex, France. 2Département de Radiothérapie, Institut de Cancérologie de la Loire - Lucien Neuwirth, 42270, Saint Priest en Jarez, France. 3Département d’Oncologie Médicale, Institut de Cancérologie de la Loire - Lucien Neuwirth, 42270, Saint Priest en Jarez, France. 4Dysfonction Vasculaire et Hémostase, INSERM, U1059, Saint-Etienne, France. 5Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 69495, Pierre-Bénite, France. Claire Rodríguez-Lafrasse and Nicolas Magné contributed equally to this work. Correspondence and requests for materials should be addressed to N.M. (email: nicolas.magné@icloire.fr)
with a central role being played by human epidermal growth factor receptor (HER) family members (HER2 or erbB2, HER3 or erbB3, HER4 or erbB4). These receptors activate downstream signalling cascades including MAPK and PI3K/AKT through ligand-dependent homo- or heterodimerization, and thus enhance cell proliferation, angiogenesis, invasion and metastasis. Pertuzumab is an HER2 antagonist directed against the extracellular dimerization domain (subdomain II), and which blocks the ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR or HER1, HER3 and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signalling through MAPK and PI3K/AKT. Interestingly, the HER2 and HER3 receptors are often expressed in HNSCC, making them potential new therapeutic targets. Many ongoing studies are using pan-HER inhibitors in HNSCC, focusing on pan-HER tyrosine kinase inhibitors (clinicaltrials.gov: NCT02216916; Molecule: HM781-36B irreversible pan-HER inhibitor). Very few data exist on the HER2–HER3 blockade and invasion/migration in HNSCC. The combination of cetuximab with pertuzumab could block HER1, 2 and 3 and therefore target the major downstream signalling cascade of migration, proliferation and survival. The aim of the present study was to explore the effect of a pan-HER blockade on the proliferation, migration and invasion of human HNSCC cells and their corresponding CSC subpopulation, through combined treatment with cetuximab and pertuzumab, with or without photon irradiation.

Figure 1. Basal characteristics of SQ20B cells, SQ20B-CSCs and FaDu cells. (A) EGFR (180 kDa), HER2 (184 kDa) and HER3 (189 kDa) basal expression in SQ20B cells, SQ20B-CSCs and FaDu cells. Protein expression was analysed with WES™ (a simple western blotting technique using an automated capillary-based size sorting system) and expressed graphically as the GAPDH ratio. (B) Phospho-AKT (Ser473) (63 kDa) and phospho-MEK1/2 (Ser217/221) (52 kDa) basal expression in SQ20B cells, SQ20B-CSCs and FaDu cells. Protein expression was analysed with WES™, and expressed graphically as the GAPDH ratio (protein-of-interest (POI)/GAPDH). (C) Microscopic observation (63×) of SQ20B cells stained with phalloidin (green actin) and DAPI (blue nucleus). (D) Microscopic observation (63×) of SQ20B-CSCs stained with phalloidin (green actin) and DAPI (blue nucleus). (E) Microscopic observation (63×) of a SQ20B cell stained with phospho-EGFR-FITC (green) and DAPI (blue nucleus). (F) Microscopic observation (63×) of a SQ20B-CSC stained with phospho-EGFR-FITC (green vacuoles) and DAPI (blue nucleus). Statistically significant differences are expressed as *p < 0.05, **p < 0.01 and ***p < 0.001. Each experiment was performed in triplicate.
Results

Basal cellular characteristics.  

**HER family expression.**  
EGFR was highly overexpressed in SQ20B cells, however the opposite occurred in SQ20B-CSCs and FaDu cells, in which EGFR was expressed at much lower levels \((P < 0.001)\). HER2 and HER3 were expressed at almost equal levels in the three populations. HER2 expression was twice as high as that of EGFR in SQ20B-CSCs and FaDu cells \((P = 0.003)\) (Fig. 1A).

**Downstream signaling.**  
Phospho-AKT expression was twice as high in SQ20B cells as in SQ20B-CSCs \((P = 0.0018)\). By contrast, Phospho-MEK1/2 expression in SQ20B cells was half that in SQ20B-CSCs \((P < 0.001)\). Phospho-AKT and Phospho-MEK1/2 \((P = 0.003)\) were expressed less in FaDu cells (Fig. 1B).

**Phenotypic characteristics.**  
SQ20B cells displayed an epithelial phenotype, with many cell–cell junctions (Fig. 1C), whereas SQ20B-CSCs were organized in a mesenchymal phenotype with a tapered and sharp actin network (Fig. 1D). Under basal conditions, EGFR was localized on the cell membranes of SQ20B cells (Fig. 1E), and mostly within intracellular vacuoles in SQ20B-CSCs (Fig. 1F).

**Cell proliferation.**  
Cetuximab significantly inhibited SQ20B \((P < 0.001)\) and FaDu \((P < 0.001)\) proliferation, whereas it had no effect on SQ20B-CSC proliferation \((p = 0.8)\) (Fig. 2 and Table 1). No effect was observed with pertuzumab alone in any cell population. However, the cetuximab–pertuzumab mixture significantly decreased cell proliferation in SQ20B and FaDu populations, and decreased cell proliferation significantly more than cetuximab alone in all three cell populations \((P < 0.001)\). Applying 10 Gy photon irradiation alone dramatically decreased SQ20B cell proliferation, and decreased SQ20B-CSC proliferation to a lesser degree. Pan-HER blockade with the addition of 10 Gy photon irradiation was more effective than 10 Gy alone in inhibiting the cell proliferation of SQ20B \((P < 0.001)\), SQ20B-CSCs \((P = 0.046)\) and FaDu \((P < 0.001)\).

**Cetuximab and/or pertuzumab synergized with irradiation to kill HNSCC cells.**  
Isobolographic analyses show that cetuximab–pertuzumab and radiation effects were always synergistic, irrespective of the...
human cell line concerned (see Supplementary Table S1). By contrast, pertuzumab alone was an antagonist in SQ20B-CSCs and FaDu, as is cetuximab alone in SQ20B-CSCs.

**Cell migration and invasion.** The cetuximab–pertuzumab mixture inhibited both migration and invasion in the three populations (Figs 3 and 4; Tables 2 and 3). The dual treatment decreased SQ20B-CSC migration and invasion more effectively than cetuximab alone ($P < 0.001$ and $P < 0.001$) (Figs 3 and 4; Tables 2 and 3). Adding pertuzumab increased effect of cetuximab on migration in all cell populations (SQ20B, $P = 0.0086$; SQ20B-CSCs, $P < 0.001$; and FaDu, $P = 0.0491$). Alone, 10 Gy photon irradiation appeared to have little effect on cell migration and invasion, as did pertuzumab alone. Furthermore, SQ20B-CSCs invaded and healed the wound faster than SQ20B cells (complete wound healing for SQ20B $\approx 40$ hours; complete wound healing for SQ20B-CSCs $\approx 30$ hours). SQ20B-CSCs migrated alone, without cell–cell junctions and a mesenchymal phenotype, in contrast to SQ20B cells (Supplementary Fig. S1).

**Protein expression.** Phospho-EGFR expression was decreased by cetuximab in SQ20B and FaDu cell lines. Cetuximab–pertuzumab in combination with 10 Gy photon irradiation significantly decreased EGFR activation in SQ20B and FaDu cells ($P = 0.043$ and $P < 0.001$, respectively), but not in SQ20B-CSCs (Fig. S5A–C). The combined treatment with cetuximab–pertuzumab and 10 Gy irradiation significantly decreased phospho-AKT in SQ20B cells ($P = 0.002$), and SQ20B-CSCs ($P = 0.042$). In the same way, the triple treatment significantly decreased Phospho-MEK1/2 in SQ20B cells ($P < 0.001$), SQ20B-CSCs ($P = 0.041$) and FaDu cells ($P = 0.05$). Photon irradiation appeared to increase EGFR phosphorylation in SQ20B and FaDu cells. Interestingly, pertuzumab alone activated EGFR in SQ20B-CSCs. The activation or inactivation of phospho-HER2 and phospho-HER3 did not show any significant differences between the different treatment conditions, and remained extremely low.

**Discussion**

The development of resistance to anticancer drugs represents a major obstacle for modern oncology, and understanding cetuximab resistance mechanisms might be the key to improving the outcomes of HNSCC patients. In the present study, we investigated mechanisms of resistance to cetuximab, and demonstrated that HER family members are key central checkpoints. We found that pan-HER blockade significantly inhibited proliferation, invasion and migration in three different HNSCC cell populations.

SQ20B-CSCs were confirmed to be resistant to conventional treatment. Our study confirmed the presence of a highly invasive CSC intrinsic population (SQ20B-CSCs) with mesenchymal characteristics, and which is
resistance to concomitant cetuximab plus RT. EGFR was highly expressed in SQ20B cells but under-expressed in CSCs, as has been previously demonstrated in HNSCC CSCs, and in another HNSCC population. Interestingly, HER2 and HER3 were expressed at the same level in the three cell populations. These family members are frequently expressed in cell lines studied in the current literature, and might be keys to enhancing therapeutic efficacy against HNSCC. Moreover, these receptors are working together, and are even dependent on each other because of their intrinsic characteristics (Fig. 1). In parallel, our cells showed striking differences in their signalling pathways. When SQ20B cells activated the AKT-mTOR pathway (increased phospho-AKT), SQ20B-CSCs activated the RAS-MAPK pathway (increased phospho-MEK1/2). Increasing attention has been paid in recent years to targeting the PI3K-AKT-mTOR pathway, largely with tyrosine kinase inhibitors (TKIs). Our study revealed that CSCs could escape this pathway by favouring the RAS-MAPK pathway. This observation leads us to think that the upstream extracellular blockade may be more effective than the downstream blockade with TKIs.

We studied here a pan-HER mixture using cetuximab and pertuzumab. Both drugs have been validated clinically. This synergistic combination blocked HER members, their cross-phosphorylation and their downstream signalling. However, our results confirmed that EGFR is the key trigger in HNSCC cell signalling. Pertuzumab alone is inefficient, and seemed to increase EGFR phosphorylation in some cases. By contrast, the combination with cetuximab was synergistic and confirmed the hypothesis of an escape mechanism via HER2 or HER3 co-receptors. In a study published by Wheeler et al., cells exposed to cetuximab for weeks developed an overexpression of HER2 and HER3. In fact, HER homo- and heterodimers form a highly redundant group of receptor complexes and thereby add to the complexity of EGFR signalling. Dimerization stimulates HER cytoplasmic kinase activity, leading to auto- and trans-phosphorylation on tyrosine residues, which serve as docking sites for adaptor proteins and enzymes. Survival can be promoted by the constitutive activation of signalling pathways downstream of EGFR, through the mutation or upregulation of other HER family receptors or other receptor tyrosine kinase classes. A high level of activated Akt can occur downstream of the EGFR inhibition through upstream-activated Src, Ras or mutated phosphatase and tensin homolog (PTEN); amplification of the catalytic

Figure 3. Cell migration under each treatment condition, graphically represented by the mean migration curves +/− standard deviation. Blue curve, control; black curve, pertuzumab 20 μg/mL; red curve, cetuximab 5 nM; green curve, cetuximab 5 nM + pertuzumab 20 μg/mL. Cell migration was measured by an IncuCyte Zoom scratch wound analyser for each cell line under the following treatment conditions: control; cetuximab 5 nM; pertuzumab 20 μg/mL; cetuximab 5 nM + pertuzumab 20 μg/mL; 10 Gy; 10 Gy + cetuximab 5 nM; 10 Gy + pertuzumab 20 μg/mL; 10 Gy + cetuximab 5 nM + pertuzumab 20 μg/mL. Each experiment was performed in triplicate.
subunit of PI3K; or loss of the PTEN tumour suppressor protein. Finally, overexpression of six major HER family ligands can activate HER receptors, resulting in resistance to EGFR inhibition.

Moreover, data suggest that EGFR functionality can also be dependent on its subcellular location. EGFR undergoes translocation into different organelles, where it elicits functions distinctly different from its well-known activity as a plasma membrane-bound receptor tyrosine kinase. Several observations suggest that EGFR can be shuttled into the cell nucleus and mitochondrion upon ligand binding, radiation, EGFR-targeted therapy and other stimuli. Nuclear EGFR behaves as a transcriptional regulator and seems to be an indicator of poor clinical outcomes. In our study, microscopic observation confirmed that the location of EGFR in CSCs is probably intra-cytoplasmic and therefore inaccessible to outer-membranous antibodies. Nuclear EGFR could be a promising therapeutic target according to some studies. Mitochondrial EGFR also appears to regulate apoptosis, and some authors suggest that EGFR prevents autophagy.

A striking effect of the cetuximab–pertuzumab combination on cell motility was observed. This combination inhibited both migration and invasion in the three cell populations. This inhibition was correlated with down-regulation of both AKT–mTOR and Ras–MAPK signalling (Fig. 5). Targeting these downstream signalling pathways is of major interest in HNSCC. It has been suggested that EGFR can induce epithelial–mesenchymal transition-like changes, leading to invasion and migration through action on the extracellular matrix. Our study demonstrated that HER2 and HER3 are also involved in cell motility. Data from other studies suggest that radiation enhances invasion/migration. This effect was not observed in our study, because of the type of experiment (scratch wound) and irradiation doses. A limit of this therapeutic combination is, of course, treatment tolerance, as the treatment has been shown to be toxic in a study of colon cancer patients. These results should be extrapolated to the clinic with caution, knowing that in vitro conditions only partially represent clinical reality. However, preliminary work on dose reduction indicated that the therapeutic effectiveness of the dual treatment could be maintained after reducing the dose of cetuximab by 50% (Supplementary Data Fig. S2), thereby reducing toxicity to a manageable level.

Figure 4. Cell invasion under each treatment condition, graphically represented by the mean invasion curves +/− standard deviation. Blue curve, control; black curve, pertuzumab 20 μg/mL; red curve, cetuximab 5 nM; green curve, cetuximab 5 nM + pertuzumab 20 μg/mL. Cell invasion was measured by an IncuCyte Zoom scratch wound analyser for each cell line under the following treatment conditions: control; cetuximab 5 nM; pertuzumab 20 μg/mL; cetuximab 5 nM + pertuzumab 20 μg/mL; 10 Gy; 10 Gy + cetuximab 5 nM; 10 Gy + pertuzumab 20 μg/mL; 10 Gy + cetuximab 5 nM + pertuzumab 20 μg/mL. Reduced Matrigel (dilution 1/10) was set into each wound. Each experiment was performed in triplicate.
To conclude, this study shows that conventional treatments, such as cetuximab with concomitant RT, are missing a cell-resistant CSC subpopulation. It also demonstrates that better knowledge of the mechanisms of cellular resistance in HNSCC could lead us to propose new drug-combinations in association with photon radiation to increase therapeutic efficacy. If recent technological developments in modern RT improve the efficacy/tolerance ratio, antibody combinations targeting the entire HER family in association with photon radiation may become major weapons for reversing cancer resistance.

Methods

Cell culture. The HNSCC SQ20B cell line was derived from a recurrent laryngeal cancer (John Little, USA). This cell line is p53-mutated and Human Papilloma Virus-negative. The HNSCC FaDu cell line (obtained from the American Type Culture Collection [ATCC], USA) was derived from an oropharyngeal cancer, and used in parallel with SQ20B cells. CSCs (SQ20B-CSCs) were obtained as previously described^30,31.

Irradiation. Photon irradiation was performed with an X-RAD320 irradiator (Precision X-ray Inc., North Branford, CT, USA) at the Faculty of Medicine in Lyon Sud of the Université Lyon 1 (UMS2444/US8 platform, France), at a dose rate of 2 Gy/min. The total irradiation dose was 10 Gy for proliferation, migration and invasion assays, and for protein expression analysis.

Drugs. Cetuximab (C-225, Merck Serono, Darmstadt, Germany) and pertuzumab (Roche SAS, Boulogne-Billancourt, France) were provided by the Pharmaceutical Department of the Centre Hospitalier Universitaire Lyon-Sud (Pierre Bénite, France). Cetuximab was used at a 5 nM concentration, as previously described^6. Pertuzumab was used at a 20 μg/mL concentration, following published methods^32. Cells were treated with cetuximab and/or pertuzumab 1 h before 10 Gy irradiation.

Figure 5. Treatment impact on protein expression. The expression of phospho-EGFR (Tyr1068) (182 kDa), phospho-AKT (Ser473) (63 kDa) and phospho-MEK1/2 (Ser217/221) (52 kDa) was evaluated under the following treatment conditions: control; cetuximab 5 nM; pertuzumab 20 μg/mL; cetuximab 5 nM + pertuzumab 20 μg/mL; 10 Gy; 10 Gy + cetuximab 5 nM; 10 Gy + pertuzumab 20 μg/mL; 10 Gy + cetuximab 5 nM + pertuzumab 20 μg/mL. Ratios of phospho-EGFR, phospho-AKT and phospho-MEK to GAPDH expression (41 kDa) were calculated and are graphed as (protein-of-interest (POI)/GAPDH). (A) SQ20B. (B) SQ20B-CSCs. (C) FaDu. Statistically significant differences are expressed as * p < 0.05, ** p < 0.01 and *** p < 0.001. Each experiment was performed in triplicate.
Microscopy. Phalloidin staining was performed to study actin, and EGFR was stained to study its cellular localization. Briefly, $2 \times 10^5$ cells were seeded in a six-well plate on slats and permeabilized with 4% paraformaldehyde, then blocked with a 10% PBS–foetal bovine serum solution. For phalloidin staining, cells were incubated in a 1% PBS–BSA solution with 1/5000 DAPI (Sigma-Aldrich, Saint-Louis, MO, USA) and 1/200 phalloidin-fluorescein antibody (Sigma-Aldrich). For EGFR staining, cells were incubated in 0.1% PBS–Triton solution for 2 h with 1/100 EGFR primary antibody (sc-03; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Then cells were incubated in a 0.1% PBS–Triton solution for one hour with 1/200 anti-rabbit FITC secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 1/5000 DAPI. Sections were mounted using glass coverslips and mounting medium (Sigma-Aldrich), and then visualized on a Zeiss fluorescence microscope (AxioImager Z2, Zeiss, Oberkochen, Germany).

Cell proliferation. The IncuCyte ZOOM® live cell imaging system (Essen BioScience, Ann Arbor, MI, USA) was used to measure cell proliferation. Cells ($3 \times 10^5$) were plated in 96-well plates for 16 h. Each well was treated according to different conditions (control, 5 nM cetuximab; 20 μg/mL pertuzumab; 5 nM cetuximab + 20 μg/mL pertuzumab) and irradiated at 10 Gy for 1 h after treatment. Growth curves (proliferation) were built from confluence measurements acquired during round-the-clock kinetic imaging (one picture every two hours). The cell confluence was measured for 120 h. Each experiment was performed in triplicate.

Migration and invasion assays. For migration and invasion assays, cells were plated in 96-well ImageLock plates (Essen BioScience). SQ20B and FaDu cells ($4 \times 10^5$) and SQ20B-CSCs ($3.5 \times 10^5$) were plated for 16 h to achieve 90–100% confluence. Then the plates were scratched with a 96-well WoundMaker™ (Essen BioScience). For the invasion assays, 50 μL of reduced Matrigel (dilution 1/10; BD Biosciences, Franklin Lakes, NJ, USA) was added to each well. Migration/invasion was detected by IncuCyte scanning one image per well, every 2 h, for 30 h for migration and 40 h for invasion. The time course of cell migration/invasion was quantified using IncuCyte ZOOM software, measuring the relative wound density (as a percentage) for each condition over time. Each experiment was performed in triplicate.

Protein expression levels. Cell pellets were lysed in 50 mM Tris buffer (pH 8.0), 150 mM NaCl, 1% Triton X-100, protease inhibitors (Complete Mini, Roche) and anti-phosphatases (PhosSTOP, Roche) for 1 h at 4°C. Lysates were centrifuged for 20 min at 15000 × g at 4°C. Protein expression studies were performed by WES, an automated capillary-based size sorting system (ProteinSimple, San Jose, CA, USA)31,32. Data were analyzed using

| SQ20B         | T50 (h) [CI95%] | p-value (Vs Control) | p-value (Vs 10 Gy) | p-value (Vs Cetuximab) |
|---------------|-----------------|----------------------|--------------------|------------------------|
| Control       | 15.5 [12.9–18.1]| —                    | —                  | —                      |
| Pertuzumab    | 15.4 [12.8–17.9]| 0.94                 | —                  | —                      |
| Cetuximab     | 37.8 [31.5–44.1]| <0.001               | —                  | —                      |
| Cetuximab + Pertuzumab | 52.6 [43.4–61.8] | <0.001               | —                  | 0.0086                 |
| 10 Gy         | 19.7 [15.8–23.6]| —                    | —                  | —                      |
| 10 Gy + Pertuzumab | 17 [13.7–20.3]  | 0.3                  | —                  | —                      |
| 10 Gy + Cetuximab | 43.6 [34.9–52.2]| <0.001               | —                  | —                      |
| 10 Gy + Cetuximab + Pertuzumab | 69.3 [54.4–84.2]| <0.001               | —                  | 0.0133                 |

| SQ20B-CSCs    | T50 (h) [CI95%] | p-value (Vs Control) | p-value (Vs 10 Gy) | p-value (Vs Cetuximab) |
|---------------|-----------------|----------------------|--------------------|------------------------|
| Control       | 20 [13.3–26.6]  | —                    | —                  | —                      |
| Pertuzumab    | 23.7 [15.6–31.7]| 0.49                 | —                  | —                      |
| Cetuximab     | 19.2 [12.7–25.7]| 0.86                 | —                  | —                      |
| Cetuximab + Pertuzumab | 54.8 [36.2–73.4] | <0.001               | —                  | <0.001                 |
| 10 Gy         | 20.9 [13.8–27.9]| —                    | —                  | —                      |
| 10 Gy + Pertuzumab | 31.4 [20.8–41.9]| 0.093               | —                  | —                      |
| 10 Gy + Cetuximab | 19 [12.5–24.5]  | 0.7                  | —                  | —                      |
| 10 Gy + Cetuximab + Pertuzumab | 71.1 [45.6–96.6]| <0.001               | —                  | <0.001                 |

| FaDu          | T50 (h) [CI95%] | p-value (Vs Control) | p-value (Vs 10 Gy) | p-value (Vs Cetuximab) |
|---------------|-----------------|----------------------|--------------------|------------------------|
| Control       | 16.3 [11.8–20.8]| —                    | —                  | —                      |
| Pertuzumab    | 15.8 [11.5–20.1]| 0.89                 | —                  | —                      |
| Cetuximab     | 31 [22.6–39.4] | 0.0011               | —                  | —                      |
| Cetuximab + Pertuzumab | 46 [33.4–58.5] | <0.001               | —                  | 0.0491                 |
| 10 Gy         | 17.1 [12.4–21.8]| —                    | —                  | —                      |
| 10 Gy + Pertuzumab | 23.2 [16.9–29.5]| 0.11                | —                  | —                      |
| 10 Gy + Cetuximab | 31.6 [22.9–40.2]| 0.0017               | —                  | —                      |
| 10 Gy + Cetuximab + Pertuzumab | 99.6 [70.2–129]| <0.001               | —                  | <0.001                 |

Table 2. Cell migration expressed with time to heal 50% of the wound (T50) and p-values. Leg. T50 (h): time to heal 50% of the wound in hours; CI95%: confidence interval; Vs: versus; Gy: Gray.
Compass software (ProteinSimple, San Jose, CA, USA). The primary antibodies used were EGFR (sc-03; Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-EGFR (Tyr1068; Cell Signaling Technology, Danvers, MA, USA), HER2 (Cell Signaling Technology), HER3 (Cell Signaling Technology), phospho-HER2 (Y1221/1222) (Cell Signaling Technology), phospho-HER3 (Y1283) (Cell Signaling Technology), phospho-AKT (Ser473; Cell Signaling Technology) and phospho-MEK1/2 (Ser217/221; Cell Signaling Technology) at a 1/50 dilution, and GAPDH (Santa Cruz Biotechnology) was used as a reference. Protein expressions are represented as digitized images of blotting by quantitative chemiluminescence. Each experiment was performed in triplicate.

Cell Cycle analysis. Cells (1 × 10^6) were plated in 25 cm² BD Falcon flasks (BD Falcon, Franklin Lakes, NJ, USA) for 16 h. Cells were treated according to the drug combinations specified previously, and irradiated at 10 Gy for 1 h after treatment. The cells were then harvested, centrifuged, washed once with PBS and fixed in cold 70% ethanol for at least 24 h at -20 °C. Fixed cells were centrifuged at 300 × g for 5 min and resuspended in PBS. Cells were then incubated for 30 min at room temperature in the dark in a 1/50 dilution, and GAPDH (Santa Cruz Biotechnology) was used as a reference. Protein expressions are represented as digitized images of blotting by quantitative chemiluminescence. Each experiment was performed in triplicate.

Table 3. Cell invasion expressed with time to heal 50% of the wound (T50) and p-values. Leg. T50 (h): time to heal 50% of the wound in hours; CI95%: confidence interval; Vs: versus; Gy: Gray.

|          | T50 (h) [CI95%] | p-value (Vs Control) | p-value (Vs 10 Gy) | p-value (Vs Cetuximab) |
|----------|----------------|----------------------|--------------------|------------------------|
| SQ20B    |                |                      |                    |                        |
| Control  | 29.1 [14.6–43.6] | —                    | —                  | —                      |
| Pertuzumab | 34 [17.1–50.9] | 0.67                 | —                  | —                      |
| Cetuximab | 138 [67.4–208.6] | <0.001               | —                  | —                      |
| Cetuximab + Pertuzumab | 242 [106.7–377.2] | <0.001               | —                  | 0.096                 |
| 10 Gy   | 33 [16.5–49.5] | —                    | —                  | —                      |
| 10 Gy + Pertuzumab | 22.8 [11.4–34.2] | —                    | 0.31               | —                      |
| 10 Gy + Cetuximab | 159 [74.7–243.3] | —                    | <0.001             | —                      |
| 10 Gy + Cetuximab + Pertuzumab | 230 [104.6–355.4] | —                    | <0.001             | 0.42                  |
| SQ20B-CSCs |                |                      |                    |                        |
| Control  | 19.3 [15.6–23.1] | —                    | —                  | —                      |
| Pertuzumab | 21 [16.9–25.1] | 0.53                 | —                  | —                      |
| Cetuximab | 13.8 [11.1–16.5] | 0.018                | —                  | —                      |
| Cetuximab + Pertuzumab | 26.3 [21–31.6] | 0.028                | —                  | <0.001                |
| 10 Gy   | 26.1 [19–31.2] | —                    | —                  | —                      |
| 10 Gy + Pertuzumab | 27.8 [22.3–33.3] | —                    | 0.66               | —                      |
| 10 Gy + Cetuximab | 15.8 [12.5–19.1] | —                    | <0.001             | —                      |
| 10 Gy + Cetuximab + Pertuzumab | 21.3 [16.8–25.8] | —                    | 0.17               | 0.046                 |
| FaDu    |                |                      |                    |                        |
| Control  | 186 [42.9–329] | —                    | —                  | —                      |
| Pertuzumab | 129 [31–227] | 0.5                  | —                  | —                      |
| Cetuximab | 520 [88.8–951] | 0.071                | —                  | —                      |
| Cetuximab + Pertuzumab | 652 [103–1200] | 0.032                | —                  | 0.92                  |
| 10 Gy   | 472 [99.6–844] | —                    | —                  | —                      |
| 10 Gy + Pertuzumab | 118 [20–216] | —                    | 0.018              | —                      |
| 10 Gy + Cetuximab | 1700 [112–3287] | —                    | 0.038              | —                      |
| 10 Gy + Cetuximab + Pertuzumab | 5970 [0–12830] | —                    | <0.001             | 0.059                 |

Compass software (ProteinSimple, San Jose, CA, USA). The primary antibodies used were EGFR (sc-03; Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-EGFR (Tyr1068; Cell Signaling Technology, Danvers, MA, USA), HER2 (Cell Signaling Technology), HER3 (Cell Signaling Technology), phospho-HER2 (Y1221/1222) (Cell Signaling Technology), phospho-HER3 (Y1283) (Cell Signaling Technology), phospho-AKT (Ser473; Cell Signaling Technology) and phospho-MEK1/2 (Ser217/221; Cell Signaling Technology) at a 1/50 dilution, and GAPDH (Santa Cruz Biotechnology) was used as a reference. Protein expressions are represented as digitized images of blotting by quantitative chemiluminescence. Each experiment was performed in triplicate.

Cell Cycle analysis. Cells (1 × 10^6) were plated in 25 cm² BD Falcon flasks (BD Falcon, Franklin Lakes, NJ, USA) for 16 h. Cells were treated according to the drug combinations specified previously, and irradiated at 10 Gy for 1 h after treatment. The cells were then harvested, centrifuged, washed once with PBS and fixed in cold 70% ethanol for at least 24 h at -20 °C. Fixed cells were centrifuged at 300 × g for 5 min and resuspended in PBS. Cells were then incubated for 30 min at room temperature in the dark in a 1/2000 DAPI solution. Finally, flow cytometry was conducted (using a BD FACSAria III, BD Biosciences) and the results were analysed using BD FACS Diva Software (BD Biosciences) to determine the relative DNA content. The cell cycle distribution was calculated after appropriate gating of the cell population. The results of this analysis are available in the supplementary data.

Statistical analysis. Analysis of proliferation, migration and invasion data was carried out using a non-linear mixed-effects model to take into account the longitudinal nature of the data and the potential inter-experiment variability. Proliferation data were analyzed using a generalized logistic growth model:

\[
\frac{dCC}{dt} = \lambda \times CC \times (1 - CC^\alpha)
\]

where \(CC(t)\) is the cell confluence expressed as a percentage at time \(t\), and \(CC_0\) is its initial value at \(t=0\) h. The parameters \(\lambda\) (h⁻¹) and \(\alpha\) correspond respectively to the growth rate and the curvature. Migration and invasion data were analyzed using a generalized Hill equation:
where $WC$ is the wound confluence at time $t$. The parameters and $T_{50}$ correspond respectively to the curvature and the time at which 50% of the wound was recovered. The influence of the different treatment conditions on for proliferation data and $T_{50}$ for migration and invasion data was tested. Statistical differences were assessed using likelihood ratio tests. Analyses were done with Monolix® software (Lixsoft-Incuballiance, Paris, France).

The differences between protein expressions (protein-of-interest/GAPDH) were determined by a $t$-test. The minimum level of significance was set at $p < 0.05$.

Dose−response interactions between radiation (photon therapy) and cetuximab and/or pertuzumab were evaluated using the classical isobolographic method described by Steel and Peckham. Theoretical basis and procedure for the isobologram method have been described in detail. The coordinates of the experimental point are the cetuximab and/or pertuzumab concentration and the radiation dose, which, when combined, give the level of efficacy. For a given level of efficacy, an “envelope of additivity” curve was calculated from the dose−effect curves of cetuximab and/or pertuzumab combined with irradiation (one dose of 10 Gy) and from the dose−effect curves of radiation alone (one dose of 10 Gy). If the experimental point falls above, beyond or under the limits of the “envelope of additivity”, cetuximab and/or pertuzumab and radiation in combination give rise to antagonistic, additive or synergistic effects, respectively.

**Availability of data and materials.** All data generated or analysed during this study are included in this published article.

**References**

1. O’Sullivan, B., Rumble, R. B. & Warde, P. & Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of head and neck cancer. *Clin. Oncol. R. Coll. Radiol. G. B.* **24**, 474–487 (2012).
2. Kalyankrishna, S. & Grandis, J. R. Epidermal growth factor receptor biology in head and neck cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **24**, 2666–2672 (2006).
3. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* **354**, 567–578 (2006).
4. Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol.* **11**, 21–28 (2010).
5. Moon, C., Chae, Y. K. & Lee, J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. *Exp. Biol. Med. Maywood N J.* **235**, 907–920 (2010).
6. Cooper, J. S. et al. National Cancer Database report on cancer of the head and neck: 10-year update. *Head Neck 31*, 748–758 (2009).
7. Moncharmont, C. et al. Targeting a cornerstone of radiation resistance: cancer stem cell. *Cancer Lett.* **322**, 139–147 (2012).
8. Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. *Proc. Natl. Acad. Sci. USA* **104**, 973–978 (2007).
9. Moncharmont, C. et al. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC). *Oncotarget 7*, 47738–47749 (2016).
10. Wheeler, D. L. et al. Mechanisms of acquired resistance to cetuximab: role of HER (Erbb) family members. *Oncogene 27*, 3944–3956 (2008).
11. Pollock, N. I. & Grandis, J. R. HER2 as a therapeutic target in head and neck squamous cell carcinoma. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **21**, 526–533 (2015).
12. Takkitika, M. et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. *J. Transl. Med.* **9**, 126 (2011).
13. Tebbutt, N., Pedersen, M. W. & Johns, T. G. Targeting the Erbb family in cancer: couples therapy. *Nat. Rev. Cancer* **13**, 663–673 (2013).
14. La Fleur, L., Johansson, A.-C. & Roberg, K. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. *PloS One 7*, e44071 (2012).
15. Simpson, D. R., Mellen, L. K. & Cohen, E. E. W. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. *Oral Oncol.* **51**, 291–298 (2015).
16. Yarden, Y. & Shliwkowski, M. X. Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell Biol.* **2**, 127–137 (2001).
17. Zhan, M. & Han, Z. C. Phosphatidylinositol3-kinase/AKT in radiation responses. *Histol. Histopathol.* **19**, 915–923 (2004).
18. Pedero, J. M. G. et al. Frequent genetic and biochemical alterations of the PI3K-AKT/PTEN pathway in head and neck squamous cell carcinoma. *Int. J. Cancer 114*, 242–248 (2005).
19. Okami, K. et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. *Cancer Res. 58*, 509–511 (1998).
20. Motoyama, A. B., Hynes, N. E. & Lane, H. A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. *Cancer Res.* **62**, 3151–3158 (2002).
21. Carpentier, J. L. et al. Subcellular distribution of the external and internal domains of the EGF receptor in A-431 cells. *Exp. Cell Res.* **166**, 312–326 (1986).
22. Han, W. & Lo, H.-W. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. *Cancer Lett.* **318**, 124–134 (2012).
23. Dittmann, K. et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. *J. Biol. Chem.* **280**, 31182–31189 (2005).
24. Brand, T. M. et al. Nuclear EGFR as a molecular target in cancer. *Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol.* **108**, 370–377 (2013).
25. Boerner, J. L., Denmory, M. L., Silva, C. & Parsons, S. J. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. *Mol. Cell Biol.* **24**, 7059–7071 (2004).
26. Weihua, Z. et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. *Cancer Cell 13*, 385–393 (2008).
27. Zuo, J.-H. et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. *J. Cell. Biochem.* **112**, 2508–2517 (2011).
28. Robinzon, D. A. et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. *Invest. New Drugs 32*, 113–122 (2014).
29. Méry, B. et al. Preclinical models in HNSCC: A comprehensive review. *Oncol. Res. 65*, 51–56 (2017).
30. Bertrand, G. et al. Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. *Stem Cell Res. 10*, 114–126 (2014).
31. Gilormini, M. et al. Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics. J. Vis. Exp. JoVE, https://doi.org/10.3791/53958 (2016).
32. El-Sahwi, K. et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br. J. Cancer 102, 134–143 (2010).
33. Beccano-Kelly, D. A. et al. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front. Cell. Neurosci. 8, 301 (2014).
34. Muntíón, S. et al. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. PloS One 11, e0146722 (2016).
35. Lavielle, M. Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools (CRC Press, 2014).
36. Samson, A., Lavielle, M. & Mentré, F. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model. Stat. Med. 26, 4860–4875 (2007).
37. Steel, G. G. & Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85–91 (1979).
38. Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621–681 (2006).

Acknowledgements
We thank everyone who participated in the experiments and acknowledge the contribution of the flow cytometry platform of the SFR BioSciences Gerland-Lyon Sud (UMS3444/US8). This work was financed by Labex Primes (ANR-11-LABX-0063), within the scientific framework of ETOILE (CPER 2009–2013) and a Lyric Grant (INCa-DGOS-4664).

Author Contributions
Jean-Baptiste Guy performed all the experiments, analysed the data and wrote and edited the manuscript. Edouard Ollier performed the statistical analysis. Benoîte Méry, Sophie Espenel, Alexis Vallard, Anne-Sophie Wozny, Stéphanie Simonet, Alexandra Lauret, Priscilla Battiston-Montagne, Dominique Ardail, Gersende Alphonse, Chloé Rancoule, helped with the experiments and technical analysis. Claire Rodriguez-Lafrasse and Nicolas Magné participated in manuscript editing and reviewing. All authors read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-12367-7.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017